Search Results - therapeutics+%3e+oncology+%3e+oncology+(small+molecules)

34 Results

Sort By:

Antitumor activity of NKTR-214 alone or in combination with anti-PD-1 therapy in tumors resistant to anti-PD-1 (UCLA Case No. 2019-254)

UCLA researchers have discovered a therapy for anti-PD-1 resistant tumors in colon carcinoma patients. A small molecule therapeutic alone or in combination with immune-checkpoint blockade (ICB) therapy exhibits tumor remission even in sublines with mutated signalling pathways that have rendered them ICB resistant. BACKGROUND: Immunotherapy, the...

Published: 2/15/2024 | Inventor(s): Antoni Ribas

Keywords(s): Colon carcinoma, Immune checkpoint blockade, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), PD-1, PD-L1, Resistant tumors, Signaling pathways, Small molecule therapeutics, Tumor

Category(s): Life Science Research Tools, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

2022-301 Multi-Specific Engineered Cytokines

SUMMARY: UCLA researchers in the Department of Bioengineering have developed a novel strategy to engineer multivalent cytokine complexes that significantly increase their selectivity towards activating effector or regulatory immune cells and reduce off-target effects in immunotherapy treatments for cancer and autoimmune diseases. BACKGROUND: In recent...

Published: 9/7/2023 | Inventor(s): Aaron Meyer

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

2022-106 A Safe, Small Molecule Drug to Prevent Kidney Cancer Metastasis

SUMMARY: UCLA researchers in the Department of Molecular and Medical Pharmacology have discovered a class of small molecule that can be given to kidney cancer patients after surgical removal of their kidney tumor(s) to prevent metastasis and increase their survival rate. BACKGROUND: Kidney cancer is the 10th most common cancer worldwide, accounting...

Published: 7/19/2023 | Inventor(s): Lily Wu

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

2021-244 MOCETINOSTAT IN COMBINATION WITH CHEMOTHERAPY TO TREAT RHABDOMYOSARCOMA

SUMMARY: Researchers at UCLA’s David Geffen School of Medicine and the UCLA Sarcoma Program have identified a treatment combination which utilizes Mocetinostat in conjunction with chemotherapy for the selective treatment of rhabdomyosarcoma. BACKGROUND: Sarcomas are a heterogeneous group of tumors arising throughout the body’s connective...

Published: 9/5/2023 | Inventor(s): Arun Singh, Noah Federman, Dennis Slamon

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules), Therapeutics > Sarcoma And Soft Tissue

2019-523 PROTEIN KINASE INHIBITORS WHICH ALSO TARGET DIHYDROOROTATE DEHYDROGENASE

SUMMARY: Researchers from UCLA’s Department of Molecular and Medicinal Pharmacology have discovered two protein kinase inhibitors that effectively inhibit dihydroorotate dehydrogenase, an enzyme linked to cancer progression. BACKGROUND: During the progression of cancer, normal healthy cells undergo mutation that converts normal cell phenotypes...

Published: 9/5/2023 | Inventor(s): Caius Radu, Evan Abt, Ethan Rosser

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Infectious Diseases, Therapeutics > Oncology > Oncology (Small Molecules)

2017-094: Inhibitors of the N-Terminal Domain of the Androgen Receptor

SUMMARYUCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.BACKGROUNDProstate...

Published: 7/19/2023 | Inventor(s): Matthew Rettig, Michael Jung

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

2022-086: NANOTECHNOLOGY FOR CHEMOTHERAPY DRUG CAPTURE

SUMMARY: UCLA researchers in the Departments of Chemical Engineering and Bioengineering and Radiological Sciences have developed a cellulose-based nanomaterial for removing excess chemotherapy drugs from the body to reduce the side-effects of cancer therapy. BACKGROUND: Cancer is one of the leading causes of death worldwide, affecting millions of...

Published: 9/5/2023 | Inventor(s): Amir Sheikhi, Ali Khademhosseini

Keywords(s):

Category(s): Materials > Nanotechnology, Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

2019-610 MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING ANTITUMOR T CELL IMMUNITY and 2019-611 MONOAMINE OXIDASE BLOCKADE THERAPY FOR TREATING CANCER THROUGH REGULATING TUMOR ASSOCIATED MACROPHAGES (TAMS)

SUMMARY UCLA researchers in the Department of Microbiology, Immunology, and Molecular Genetics identified MAO-A as a drug target and demonstrated repurposing an old antidepressant MAOI for use in combination with cancer immunotherapy methods. BACKGROUND: Monoamine Oxidase A (MAO-A) is a protein of myriad functions relating to neurotransmitter homeostasis...

Published: 9/5/2023 | Inventor(s): Lili Yang

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

Impaired Nucleotide Catabolism Renders Cancer Cells Sensitive to PNP Inhibition

UCLA researchers in the Department of Molecular and Medical Pharmacology have uncovered novel biomarkers to predict cancer sensitivity to PNP inhibitors. BACKGROUND: A common hallmark of cancer is the alteration of cellular metabolism. To sustain growth and proliferation, cancer cells must produce sufficient and balanced pools of deoxyribonucleotide...

Published: 7/19/2023 | Inventor(s): Caius Radu, Evan Abt, Thuc Le

Keywords(s): Oncology (Small Molecules, Peptides and Antibodies)

Category(s): Therapeutics > Oncology > Oncology (Small Molecules)

2015-341 COMBINATIONS OF CHECKPOINT INHIBITORS AND DENDRITIC CELL VACCINES TO TREAT BRAIN CANCER

UCLA researchers in the Departments of Neurosurgery and Molecular and Medical Pharmacology have developed an autologous dendritic cell (DC) vaccine in combination with checkpoint inhibitors for the treatment of malignant brain tumors.BACKGROUND: Checkpoint inhibitor therapies, which unblock an existing immune response, or unblock the initiation of an...

Published: 7/19/2023 | Inventor(s): Robert Prins, Linda Liau

Keywords(s): Antibodies, Drug Delivery, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), Oncology Immunotherapy, Therapeutics & Vaccines, Vaccines

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Vaccines, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

1 2 3 4